Keytruda, also known as pembrolizumab, accounts for the bulk of the Rahway, New Jersey-based pharmaceutical giant's revenue. However, with its U.S. patent exclusivity ending in 2028, Merck (NYSE ...

The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...

The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

SELLAS Life Sciences Group, Inc.’s SLS share price has surged by 21.80%, which has investors questioning if this is right time to sell.

About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.

High disease control rate and strong interim safety results observed in pancreatic cancer patients across three trials exploring the use of ...